These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36655774)

  • 21. First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape.
    Gulati S; Labaki C; Karachaliou GS; Choueiri TK; Zhang T
    Oncologist; 2022 Mar; 27(2):125-134. PubMed ID: 35641205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
    Motzer RJ; Escudier B; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Plimack ER; Procopio G; McDermott DF; Castellano D; Choueiri TK; Donskov F; Gurney H; Oudard S; Richardet M; Peltola K; Alva AS; Carducci M; Wagstaff J; Chevreau C; Fukasawa S; Tomita Y; Gauler TC; Kollmannsberger CK; Schutz FA; Larkin J; Cella D; McHenry MB; Saggi SS; Tannir NM
    Cancer; 2020 Sep; 126(18):4156-4167. PubMed ID: 32673417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
    Abdelaziz A; Vaishampayan U
    Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
    Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
    Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
    Vano YA; Phan L; Gravis G; Korakis I; Schlürmann F; Maillet D; Bennamoun M; Houede N; Topart D; Borchiellini D; Barthelemy P; Ratta R; Ryckewaert T; Hasbini A; Hans S; Emambux S; Cournier S; Braychenko E; Elaidi RT; Oudard S
    Int J Cancer; 2022 Oct; 151(8):1335-1344. PubMed ID: 35603906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma.
    Meza L; Malhotra J; Favorito C; Pal SK
    Future Oncol; 2022 Jan; 18(1):21-33. PubMed ID: 34766841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment sequences for advanced renal cell carcinoma: A health economic assessment.
    Deniz B; Ambavane A; Yang S; Altincatal A; Doan J; Rao S; Michaelson MD
    PLoS One; 2019; 14(8):e0215761. PubMed ID: 31465470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma.
    Rosellini M; Tassinari E; Marchetti A; Tateo V; Nuvola G; Rizzo A; Massari F; Mollica V
    Expert Opin Drug Saf; 2023 Apr; 22(4):279-291. PubMed ID: 37055875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
    Ornstein MC; Rini BI
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma.
    Anghelone A; Strusi A; Scala A; Panebianco M; Ciccarese C; Iacovelli R
    Expert Rev Anticancer Ther; 2023 Jul; 23(7):669-672. PubMed ID: 37246571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunotherapy for renal cell carcinoma - current status].
    Grimm MO; Foller S
    Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison.
    Porta C; Szczylik C; Casciano R; Fu S; Amzal B; Lister J; Karcher H; Meng J; Neumann M; Dinet J
    Crit Rev Oncol Hematol; 2019 Jul; 139():143-148. PubMed ID: 30401604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Gill DM; Hahn AW; Hale P; Maughan BL
    Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment.
    Nolla K; Benjamin DJ; Cella D
    Nat Rev Urol; 2023 Jul; 20(7):420-433. PubMed ID: 36928615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
    Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
    Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
    Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
    Santoni M; Aurilio G; Massari F; Grande E; Matrana MR; Rizzo M; De Giorgi U; Incorvaia L; Martignetti A; Molina-Cerrillo J; Zabalza IO; Mollica V; Rizzo A; Battelli N; Porta C
    Clin Genitourin Cancer; 2022 Jun; 20(3):285-295. PubMed ID: 35305916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma.
    Park KY; Hefti HO; Liu P; Lugo-Cintrón KM; Kerr SC; Beebe DJ
    Integr Biol (Camb); 2021 Dec; 13(11):259-268. PubMed ID: 34931665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.